Andrijević Ilija, Povazan Dorde, Andrijević Ljiljana, Povazan Anika, Milutinov Senka
Institut za plućne bolesti Vojvodine, Sremska Kamenica.
Med Pregl. 2011 Mar-Apr;64(3-4):178-82. doi: 10.2298/mpns1104178a.
The exacerbation of chronic obstructive pulmonary disease is most often induced by an infection of bacterial origin in over 50% of the cases (or mixed bacterial and viral infection). This study was aimed at evaluating clinical effects of antibiotics co-amoxiclav. Amoxiicillin with clavulanic acid in the treatment of patients with severe chronic obstructive pulmonary disease exacerbation.
The investigation included 38 patients with severe chronic obstructive pulmonary disease exacerbation hospitalized at the Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica. The patients were randomly selected for the antibiotic treatment with Amoxiclav twice a day in 12 hour intervals. The clinical effects of the applied treatment were evaluated by analyzing certain laboratory findings, microbiological sputum findings and improvement of subjective symptoms.
Of the examined subjects, 65% were males and 35% were females, their mean age being 66.4 +/- 8.86, and who were mostly smokers (73%). After the completion Of Applied antibiotic treatment, a significant reduction and normalization of all inflammation markers were recorded, as well as a significant improvement of the patients' subjective symptoms. The positive microbiological sputum findings (Haemophilus influenzae, Pseudomonas aeruginosa and Streptococcus pneumoniae) were recorded in 13.58% of the patients. The bacterial agent was eradicated on the third day of the applied treatment. The mean length of the treatment was 7.07 +/- 0.91 days, with no undesirable treatment side effects observed CONCLUSION The antibiotic therapy is justifiable as the initial treatment regimen of severe chronic obstructive pulmonary disease exacerbation and amoxicillin with clavulanic acid is reported as the first-line antibiotic drug in most pharmacotherapy guidelines.
超过50%的慢性阻塞性肺疾病急性加重是由细菌感染（或细菌与病毒混合感染）引起的。本研究旨在评估抗生素阿莫西林克拉维酸在治疗重度慢性阻塞性肺疾病急性加重患者中的临床效果。
该调查纳入了38例在斯雷姆斯卡卡梅尼察伏伊伏丁那肺病研究所住院的重度慢性阻塞性肺疾病急性加重患者。患者被随机选择接受阿莫西林克拉维酸治疗，每天两次，间隔12小时。通过分析某些实验室检查结果、痰微生物学检查结果和主观症状改善情况来评估所应用治疗的临床效果。
在被检查的受试者中，65%为男性，35%为女性，平均年龄为66.4±8.86岁，且大多数为吸烟者（73%）。在完成所应用的抗生素治疗后，所有炎症标志物均显著降低并恢复正常，患者的主观症状也有显著改善。13.58%的患者痰微生物学检查结果呈阳性（流感嗜血杆菌、铜绿假单胞菌和肺炎链球菌）。在应用治疗的第三天细菌病原体被根除。治疗的平均时长为7.07±0.91天，未观察到不良治疗副作用。结论：抗生素治疗作为重度慢性阻塞性肺疾病急性加重的初始治疗方案是合理的，并且在大多数药物治疗指南中阿莫西林克拉维酸被报告为一线抗生素药物。
